NEW YORK, NY / ACCESSWIRE / March 13, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Nutanix, Inc. (NASDAQ: NTNX)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/nutanix-inc-loss-submission-form?prid=13633&wire=1
Lead Plaintiff Deadline: March 22, 2021
Class Period: March 1, 2018 - May 30, 2019

Allegations against NTNX include that: Nutanix had materially overstated its customer base and sales productivity, and that such overstatements would eventually cause the Company's stock price to drop dramatically.

Penumbra, Inc. (NYSE: PEN)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/penumbra-inc-loss-submission-form?prid=13633&wire=1
Lead Plaintiff Deadline: March 16, 2021
Class Period: August 3, 2020 - December 15, 2020

Allegations against PEN include that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.

Athenex, Inc. (NASDAQ: ATNX)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/athenex-inc-loss-submission-form?prid=13633&wire=1
Lead Plaintiff Deadline: May 3, 2021
Class Period: August 7, 2019 - February 26, 2021

Allegations against ATNX include that: Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.